This content is machine translated Tirzepatide after the menopause stage Significant reduction in KG and waist circumference In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the...…
View Post 4 min This content is machine translated Study report: Obesity New findings on the effects of incretin analogs A study by Aronne et al. investigated the effects of the dual GLP1/GIP receptor agonist (RA) tirzepatide in obese patients when it is administered over a longer period of therapy...…
View Post 3 min This content is machine translated Real-world data from tirzepatide Safety comparable to other GLP1-RA As more people with type 2 diabetes (T2D) take medication to control blood sugar levels and lose weight, safety concerns have arisen. Real-world evidence from the US Food and Drug…
View Post 3 min This content is machine translated Tirzepatide for type 2 diabetes Post-hoc analysis of the SURPASS studies The SURPASS study program investigated the efficacy and safety of the dual GIP/GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. An exploratory analysis of the Phase III SURPASS…
View Post 6 min This content is machine translated Incretin-based therapies for type 2 diabetes Evolution of therapy options continues Incretin mimetics are an attractive treatment option, particularly for the subgroup of overweight type 2 diabetics, as they not only have glucose-lowering effects, but have also demonstrated clinical benefits in…
View Post 4 min This content is machine translated Dual GIP/GLP-1 RA in type 2 diabetes Tirzepatide proves multiple benefits In the Phase III SURPASS study program, the dual receptor agonist tirzepatide performed convincingly. The results of several post-hoc analyses are now also available. At the annual meeting of the…
